alexa Progress Towards The Development Of A Chlamydial Vaccine For Koalas
ISSN: 2155-9597

Journal of Bacteriology & Parasitology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd International Congress on Bacteriology & Infectious Diseases
November 17-19, 2014 DoubleTree by Hilton Hotel Chicago-North Shore, USA

Avinash Kollipara, Jon Hanger, Jo Loader, Galit Rawlinson, Jacqui Brumm, Karen Nilsson, Adam Polkinghorne, Kenneth Beagley and Peter Timms
Accepted Abstracts: J Bacteriol Parasitol
DOI: 10.4172/2155-9597.S1.008
Wild koala populations continue to experience serious declines as a result of factorsincluding, (i) loss of habitat, (ii) motor vehicle trauma; (iii) dog attacks; (iv) chlamydial disease. Modeling shows that targeting chlamydial diseasewould have the greatest potential impact on stabilizing population decline.In the koala, chlamydial infections have been associated with diseases ranging from ocular disease leading to blindness, as well as urinary and genital tract disease. An effective vaccine to prevent the adverse consequences of chlamydial infections in koalas would provide an important management tool to stop the population decline in this species. In the first trial we vaccinated groups of captive healthy koalas via the subcutaneous route, using the chlamydial MOMP antigen. We observed good serum and vaginal secretion antibodies as well as specific lymphocyte proliferation responses.In the next trial we utilised a recombinant MOMP protein, cloned from a C.pecorum koala isolate. We vaccinated two groups of koalas, (i) wild caught animals that were clinically healthy and Chlamydia PCR negative, (ii) wild caught animals that had clinical signs of disease.Following vaccination, there was no increase in inflammatory pathological changes in any animals. Strong antibody (including neutralizing antibodies) and lymphocyte proliferation responses occurred in all vaccinated koalas.In the third trial we compared three genotypes of MOMP, designatedto match the circulating genotypes in wild populations and demonstrated promising cross-strain immune responses. In the fourth trial, which we are just completing, we have obtained good immune responses in male koalas. So far, we have shown that a multi-subunit chlamydial vaccine can be safely administered to both healthy koalas as well as koalas that have a previous or current chlamydial infection. Specific anti-MOMP antibodies are produced at high levels and, importantly, these antibodies are neutralizing in vitro. Equally importantly, these antibodies from immunized animals (but not from naturally infected animals) were able to cross neutralize other MOMP types, suggesting that induction of immunity against multiple genotypes may be possible.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version